I acquired the M.D. from Wuhan University School of Medicine in 1994 and Ph.D. from the Institute of Molecular and Cell Biology (IMCB) at Singapore in 2002. Between 2003 and 2007, I received my postdoctoral training in IMCB and Johns Hopkins University School of Medicine. I am the co-author of 40 plus scientific publications mostly in peer-reviewed international journals including PNAS, Cancer Res., J. Biol. Chem. and Oncogene. Those publications have been cited more than 1,000 times and H index=16.

Research Interests

We are a laboratory in tumor pathology study. Currently, we are focusing on elucidation of 1) The mechanisms of growth factors involved in endocrine related cancers; 2) Pathological characterization of noncoding RNA in cancer; 3) Novel therapeutic approaches for cancer treatment.

Selected Publications

1.Zhu T, Eyleen L. K. Goh, Ralph Graichen, Ling Ling, Peter E. Lobie. Signal Transduction through the Growth Hormone Receptor. Cellular Signal. (2002) 13, 599-616. Review.

2.Zhu T, Ling Ling, Peter E. Lobie. Identification of A JAK2 Independent Pathway Regulating Growth Hormone Stimulated P44/42 MAP Kinase Activity. J Biol Chem. (2002) 277, 45592-45603.

3.Zhu T, Starling B. Emerald,Hichem C. Mertani, Xin Zhang, Kok-Onn Lee, and Peter E Lobie. Oncogenic Transformation of Human Mammary Epithelial Cells by Autocrine Human Growth Hormone. Cancer Res. (2005) 65, 317-324.

4.Pandey V, Perry JK, Mohan Kumar KM, Kong XJ, Liu SM, Wu ZS, Mitchell MD, Zhu T^*, Lobie PE. Autocrine Human Growth Hormone StimulatesOncogenicity of Endometrial Carcinoma Cells. Endocrinology (2008) 8，3909-3919

5.Pandey V, Qian PX, Kang J, Perry JK, Mitchell MD, Yin ZN, Wu ZS, Liu DX, Zhu T^*, Lobie PE. Artemin stimulates oncogenicity and invasion of endometrial carcinoma cells. Endocrinology (2010) 151，909-920.

6.Tan S, Li R, Ding K, Zhu T^*.MiR-198 inhibits migration and invasion of hepatocellular carcinoma cell by targeting HGF/c-Met pathway. (2011) FEBS Lett. Jun 6. [Epub ahead of print]

7.Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G, Bieche I, Lobie PE, Davidson NE , Zaver M. Bhujwalla ZM, Zhu T^*, Sukumar S. HOXB7 renders breast cancer resistant to tamoxifen through activation of the EGFR Pathway. Proc Natl Acad Sci U S A. (2011) Jun 20. [Epub ahead of print]

8.Banerjee A, Wu ZS, Qian PX, Kang J, Pandey V, Liu DX, Zhu T^*, Lobie PE Twist1 mediates artemin stimulated metastasis of ER- mammary carcinoma. Breast Cancer Res., (2011) In press.

9.Wu ZS, Yang K, Wan Y, Qian PX, Perry JK, Mertani HC, Zhu T^*, Lobie P. Tumor expression of hGH and hPRL predict a worse survival outcome in patients with mammary and endometrial carcinoma. J. Clin. Endocrinol. & Metab., (2011), In press.

10.Zuo Z, Qian P, Wu Z, Wang P, Tan S, Li G, Zhang W, Wu Q, Pandey V, Zhao L, Song E, Lobie PE, Yin Z and Zhu T^*.  Pivotal role of let-7g in breast cancer invasion and metastasis. Cancer Res., (2011) In press.